Endothelial Hyperpolarization in Humans

Summary

The purpose of this study is to elucidate the role Endothelium-Derived Hyperpolarizing Factor (EDHF) plays in dilating blood vessels and whether it differs between healthy people and those with high cholesterol. A second purpose of the study is to determine the identity of EDHF.

Conditions

• Hyperlipidemia

Interventions

DRUG

Tetraethylammonium (TEA)

5 minute intra-arterial infusion of Tetraethylammonium at 1 mg/min

DRUG

L-NG-monomethyl Arginine (L-NMMA)

5 minute intra-arterial infusion of L-NMMA 8 μmol/min

DRUG

Bradykinin

Intra-arterial infusion of bradykinin at 100, 200, and 400 ng/min. Each dose will be given for 5 minutes.

DRUG

Sodium nitroprusside

Intra-arterial infusion of sodium nitroprusside at 1.6 and 3.2 mg/min. Each dose will be given for 5 minutes.

DRUG

Acetylcholine

Intra-arterial infusion of acetylcholine at 7.5, 15 and 30 μg/min. Each dose will be given for 5 minutes.

DRUG

Saline

5 minute intra-arterial infusion of 0.9% saline at 2.5ml/min

DRUG

Fluconazole

5 minute intra-arterial infusion of fluconazole at 0.4 mg/L/min

Sponsors & Collaborators

• National Heart, Lung, and Blood Institute (NHLBI)

  collaborator NIH

• Emory University

  lead OTHER

Principal Investigators

• Arshed A Quyyumi, MD · Emory University School of Medicine, Division of Cardiology

Study Design

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

21 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2002-07-31

Primary Completion

2013-01-31

Completion

2013-01-31

Countries

• United States

Study Locations